Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NRX Pharmaceuticals Inc (NRXP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NRXP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $32.67
1 Year Target Price $32.67
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.14% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 52.07M USD | Price to earnings Ratio - | 1Y Target Price 32.67 |
Price to earnings Ratio - | 1Y Target Price 32.67 | ||
Volume (30-day avg) 3 | Beta 1.6 | 52 Weeks Range 1.10 - 6.01 | Updated Date 08/15/2025 |
52 Weeks Range 1.10 - 6.01 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -191.74% | Return on Equity (TTM) -682.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 54923112 | Price to Sales(TTM) - |
Enterprise Value 54923112 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.15 | Shares Outstanding 19503400 | Shares Floating 13809742 |
Shares Outstanding 19503400 | Shares Floating 13809742 | ||
Percent Insiders 15.88 | Percent Institutions 13.68 |
Upturn AI SWOT
NRX Pharmaceuticals Inc
Company Overview
History and Background
NRX Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics for the treatment of central nervous system disorders, primarily suicidal depression and chronic pain. Founded in 2015, the company has advanced several compounds through clinical trials, leveraging research from the National Institutes of Health and other institutions.
Core Business Areas
- NRx Pharmaceuticals: Focuses on developing and commercializing innovative therapies primarily for central nervous system disorders, particularly those involving suicidal ideation and chronic pain. Their lead product candidates target these critical unmet needs. The company is shifting from a traditional pharma to a technology company using new approaches to drug development.
Leadership and Structure
The leadership team includes Dr. Jonathan Javitt, CEO, and other experienced professionals in drug development and commercialization. The company has a board of directors that provides strategic oversight.
Top Products and Market Share
Key Offerings
- ZYESAMIu00ae (aviptadil): Investigational drug for respiratory failure in COVID-19. Although previously in clinical trials, current focus is primarily on their CNS portfolio due to regulatory setbacks. Competitors: Gilead Sciences (Veklury), Regeneron (REGEN-COV).
- NRX-101: A fixed-dose combination of D-cycloserine and lurasidone, aimed at treating acute suicidal ideation and bipolar depression. Currently in Phase 3 trials. Key competitors in the depression market include Johnson & Johnson (Spravato), and several SSRI and SNRI medications. Market share for existing therapies is distributed among numerous pharmaceutical companies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. CNS disorders represent a significant market opportunity due to the unmet needs and large patient populations.
Positioning
NRX Pharmaceuticals is positioned as an innovator in CNS therapeutics, particularly in the areas of suicidal ideation and chronic pain. Their competitive advantage lies in their novel drug candidates and focus on addressing unmet medical needs.
Total Addressable Market (TAM)
The total addressable market for depression and suicidal ideation is estimated to be in the billions of dollars annually. NRX Pharmaceuticals aims to capture a significant portion of this market with its innovative therapies, especially NRX-101. The company's positioning focuses on a specific subsegment of patients with high unmet needs (suicidal bipolar depression).
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting unmet medical needs
- Experienced leadership team
- Strategic partnerships and collaborations
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Dependence on regulatory approvals
Opportunities
- Positive clinical trial results for NRX-101
- Expansion into new therapeutic areas
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Adverse reaction to drugs
Competitors and Market Share
Key Competitors
- JNJ
- LLY
- VRAY
Competitive Landscape
NRX Pharmaceuticals competes with established pharmaceutical companies in the CNS market. Its advantage lies in its novel drug candidates, but it faces challenges due to limited resources and the need for clinical trial success and regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily marked by advancement of clinical trial programs and strategic partnerships, rather than revenue generation.
Future Projections: Future growth is contingent on successful clinical trial outcomes, regulatory approvals, and subsequent commercialization of their drug candidates. Analyst projections are speculative and highly dependent on these factors.
Recent Initiatives: Recent initiatives include advancing NRX-101 through Phase 3 trials, seeking regulatory pathways for their drug candidates, and exploring potential partnerships for commercialization.
Summary
NRX Pharmaceuticals is a development-stage biopharmaceutical company focusing on novel CNS therapies. Its success hinges on positive clinical trial results and regulatory approvals for its lead drug candidate, NRX-101. The company faces challenges including limited financial resources and competition from established pharmaceutical companies. Progress in clinical trials represents significant opportunities for growth, while regulatory hurdles and clinical trial failures pose potential threats. Therefore, investors should monitor clinical trial outcomes carefully.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NRX Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2017-12-04 | Co-Founder, Chief Scientist Officer, Chairman & Interim CEO Dr. Jonathan C. Javitt M.D., M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.nrxpharma.com |
Full time employees - | Website https://www.nrxpharma.com | ||
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.